Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InVasc Therapeutics, a biopharmaceutical company developing drugs to mitigate risks associated with cardiometabolic diseases, has been awarded two small business innovations research (SBIR) Phase 1 grants by the National Institutes of Health (NIH).
Subscribe to our email newsletter
InVasc Therapeutics said that one grant is to continue research and development of small molecule drugs for the prevention and treatment of hypertension and stroke based on derivatives of alpha lipoic acid and the second grant is to advance the discovery and development of inhibitors of myeloperoxidase for use in treating or preventing acute vascular or inflammatory events. The aggregate funding from these two Phase 1 grants is nearly $400,000.
William Johnston, CEO of InVasc Therapeutics, said: “These grants are expected to facilitate the continued development of several early stage drug candidates in our pipeline and support our objective to file an IND application on an annual basis for several years.”
Bobby Khan, founder, director and chair of scientific advisory board at InVasc Therapeutics, said: “These grants recognise InVasc Therapeutics’ approach of derivatising naturally occurring compounds to address the needs associated with cardiovascular diseases and diabetes.
“Preliminary candidates have shown distinct activity in cellular assays for improved vascular function and favorable effects in regulating enzymes linked to cardiovascular tissue damage.”